Change in the child's moderate-to-vigorous physical activity participation [ Time Frame: From baseline to end of treatment (12 months) and follow up (6-12 months post-treatment) ] [ Designated as safety issue: No ]

Increase in health-related physical fitness [ Time Frame: From baseline to end of treatment (12 months) and follow up (6-12 months post-treatment) ] [ Designated as safety issue: No ]

Achievement of age-appropriate gross motor skills [ Time Frame: From baseline to end of treatment (12 months) and follow up (6-12 months post-treatment) ] [ Designated as safety issue: No ]

Change in the parents' and child's perceptions of physical activity importance, value, appropriateness and competence [ Time Frame: From baseline to end of treatment (12 months) and follow up (6-12 months post-treatment) ] [ Designated as safety issue: No ]

Compliance with the intervention [ Time Frame: From baseline to end of treatment (12 months) and follow up (6-12 months post-treatment) ] [ Designated as safety issue: No ]

Change in the parents’ and child’s perceptions of physical activity importance, value, appropriateness and competence

Compliance with the intervention

Current Other Outcome Measures ICMJE

Not Provided

Original Other Outcome Measures ICMJE

Not Provided

Descriptive Information

Brief Title ICMJE

Physical Activity in Fontan Patients

Official Title ICMJE

Identifying Determinants and Optimizing Rehabilitation of Physical Activity for Children After the Fontan Procedure

Brief Summary

The purpose of this study is to determine which is the most effective intervention for increasing lifestyle physical activity in Fontan patients: an education (stage of change) intervention or a physical activity (mastery experience) intervention.

Detailed Description

Over 100,000 Canadian children are living with congenital heart defects and approximately 1.5% of them have a univentricular heart. The Fontan procedure allows children with functionally univentricular hearts to live relatively normal lives. However, the cardiopulmonary physiology remains abnormal and chronic complications, including myocardial dysfunction, arrhythmias, pathway abnormalities, hepatic dysfunction, obstruction of the ventricular outflow tract or pulmonary veins, and pulmonary arteriovenous malformations may significantly reduce maximal exercise capacity and quality of life. Quality of life and life-long heart health are, therefore, critically important for Fontan patients as their survival depends on the continued functioning of an already sub-normal cardiopulmonary physiology.

Children in this arm of the study will be provided with specific activities to be completed on most days of the week. The selected activities will be based on the child's interests and results of the baseline measures of health-related PA, MVPA and gross motor skill. The resources and facilities available to the family and season of the year will also influence the choice of activities. The frequency and duration of the required activities will be gradually increased until the child's baseline MVPA has been increased by a minimum of 30 minutes per day, most days of the week. Once that increase is achieved, the activities will be modified to maintain and reinforce the higher PA level.

Behavioral: Education

Children in this arm of the study will be provided with puzzles, stories and games to be completed each week. The selected activities will be based on the child's interests and designed to increase the child's knowledge of activity options, perceptions of activity benefits, self-confidence for activity participation and motivation for daily activity. The activities introduced will vary with the resources available to the family and the season of the year, and will include information about healthy eating, injury prevention, and healthy lifestyle options.

Study Arm (s)

Experimental: 1

Intervention: Behavioral: Physical Activity

Active Comparator: 2

Intervention: Behavioral: Education

Publications *

Not Provided

* Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.